MSB

7.69%

$1.19 mesoblast limited

Anyone else buy in after todays dip/crash?, page-131

First 131 Last

Share
Profile

Follow
lukewarmtin

92 Posts.

17

11/08/20

22:29

Post #: 46467656
Share

Originally posted by Redchip68: ↑

actually the mechanism of action does not have to be demonstrated. I believe it is simply the FDA's job to raise all and any questions. They even brought up the question about single armed trial..even though it has been discussed before with the company and that it is clear you can get approved with the right single armed trial design.

my source - same document, couple of paragraphs down.
"Development of adequate potency assays, however, can be particularly challenging for MSCbased products. ......

Despite these challenges, FDA has suggested that developers of cell-based products may
progress in two relevant ways. The first is that potency assays based on reasonable hypotheses
about mechanisms of action rather than a clearly demonstrated mechanism of action may be
adequate in some circumstances. FDA has provided guidance on potency assay development that
allows a matrix approach for complex biological products, including cell therapies. This matrix
approach relies on at least one quantitative bioassay and one qualitative bioassay, which together
are sufficiently related to the proposed mechanisms of action. As for other assays for quality
attributes, potency assays used under these conditions must be sufficiently robust in terms of
reproducibility and as indicators of product quality and product stability.

The second approach is to use clinical performance to demonstrate potency. For instance, if a
product meets the primary clinical outcomes, has been extensively characterized during product
development, and is produced by a well-controlled manufacturing process, these clinical data
may be considered to demonstrate potency even if the mechanism of action is not completely
understood. In this scenario, assays purporting to measure product attributes thought to be related
to product potency must be sufficiently robust in terms of reproducibility and as indicators of
product quality and stability. This approach can allow novel therapies with clearly demonstrated
efficacy and well-controlled manufacturing processes to progress to licensure even if the
mechanism of action and its relationship to the relevant potency assay are not completely
understood."

Expand

Excellent post Redchip68.

I've run out of lightbulbs, but consider it done!

MSB Price at posting: $3.36 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

Bitcoin investors need to know the risks

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

There are more pages in this discussion • 81 more messages in this thread...

First 131 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.19		Change 0.085(7.69%)		Mkt cap ! $1.358B

Open	High	Low	Value	Volume
$1.10	$1.20	$1.09	$13.21M	11.37M

Buyers (Bids)

No.	Vol.	Price($)
1	15000	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.19	75212	5

View Market Depth

No.	Vol.	Price($)
1	15000	1.185
1	20000	1.175
1	5664	1.170
1	17568	1.160
3	56695	1.150

Price($)	Vol.	No.
1.190	59712	2
1.195	36255	5
1.200	404381	31
1.205	3000	1
1.210	162475	7

Last trade - 16.10pm 12/07/2024 (20 minute delay)

MSB (ASX) Chart

Anyone else buy in after todays dip/crash?, page-131

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

Bitcoin investors need to know the risks

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Anyone else buy in after todays dip/crash?, page-131

Top Stories

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

Bitcoin investors need to know the risks

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News